MaxCyte licenses Flow Electroporation tech and ExPERT platform to Legend Biotech for cell therapy development.

MaxCyte, a leading cell-engineering firm, signed a strategic platform license with Legend Biotech, a global cell therapy leader. Legend Biotech gets worldwide, non-exclusive rights to use MaxCyte's Flow Electroporation tech and ExPERT platform for non-viral engineered therapies with T cells, Gamma-Delta T cells, and NK cells. MaxCyte will receive annual fees, milestones, and royalties on sales.